RxDoctor Payments Data

Mehra Hosseini, MD

Gastroenterology · Berkeley, CANPI 1205947884

Payments from drug & device makers

$4,156in general payments, 2019–2025

Across 206 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$922
  • Takeda Pharmaceuticals U.S.A., Inc.$394
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$207
  • Pfizer$168
  • Merck$145
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,03397%
  • Education$782%
  • Entertainment$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,156 in reported general payments places this provider in the 60th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$215,079
Medicare patients
539
Services billed
1,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab18$400,332
Humira(Cf) PenAdalimumab24$166,016
LinzessLinaclotide63$53,138
Mesalamine57$37,938
BaracludeEntecavir17$32,982
Dexlansoprazole DrDexlansoprazole93$32,450
XifaxanRifaximin11$23,710
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates335$22,327
Pantoprazole Sodium1,195$17,509
MotegrityPrucalopride Succinate23$12,482
CreonLipase/Protease/Amylase14$9,040
MovantikNaloxegol Oxalate12$4,932
Esomeprazole Magnesium41$3,056
Famotidine169$1,838
Omeprazole105$1,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$922$400,33218 claims
AbbVieLinzess, Creon$1,245$62,17877 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$207$23,71011 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$394$12,48223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Berkeley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →